Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07188077
Recruiting Observational

Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma

NCT07188077 · tracked via the Priya Life Science China tracker
Sponsor
Ting YANG
Phase
Observational
Started
2025-03-01
Last updated
2025-11-18

Condition(s) studied

Primary Central Nervous System Lymphoma (PCNSL)Diffuse Large B-Cell Lymphoma

Study summary

This study is a prospective cohort study. The case group will include patients with primary central nervous system lymphoma confirmed by imaging and pathology. The control group will include patients with pathologically confirmed diffuse large B-cell lymphoma who have been excluded from central nervous system involvement, as well as age- and gender-matched healthy volunteers (hematopoietic stem cell donors). Baseline data (as described below) will be collected. Patients with primary CNS lymphoma will undergo follow-up every 3 months, with immediate follow-up if clinical symptoms arise.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Aged between 18 and 75 years. 2. The case group must have a confirmed diagnosis of primary central nervous system lymphoma (PCNSL) and must not have received any antitumor therapy prior to baseline sample collection. 3. Must sign an informed consent form, agree to participate in this study, and provide samples and clinical information as required. 4. Case group patients must have complete supporting imaging and pathology data. Exclusion Criteria: 1. Presence of other systemic malignancies. 2. Presence of severe infections or metabolic disorders. 3. Use of antimetabolites or chemotherapy drugs within one week prior to sample collection. 4. Pregnant or lactating women. 5. Concurrent severe internal medical conditions (e.g., end-stage renal disease, heart failure, liver failure). 6. Patients unable to complete study requirements due to psychiatric disorders or cognitive impairment.

Primary outcome measure(s)

  • Metabolomics — Before the start of the first treatment cycle, at the end of each treatment cycle(each cycle is 28 days)
    Detection of metabolites in plasma using liquid chromatography-mass spectrometry (LC-MS) technology
  • CYTOF — Before the start of the first treatment cycle, at the end of each treatment cycle(each cycle is 28 days)
    Immunophenotyping of PBMCs using flow cytometry mass spectrometry (CYTOF)

Trial sites (1)

FacilityCityRegionStatus
The First Affiliated Hospital of Fujian Medical University Fuzhou Fujian Recruiting

More Ting YANG trials in China

Lung Health of Early COPD: A Multi-center Cohort Study Recruiting
Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma Recruiting

Other trials for the same condition

R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma Recruiting
CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL Recruiting
Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma Recruiting
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Active, not recruiting
Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective Study Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07188077 on ClinicalTrials.gov ↗ ← All trials in China